Introduction. Pancreatic injury can manifest after major hepatectomy under vascular control. The main mechanism involved seems to be remote oxidative injury due to “spillage” of reactive oxygen species and cytokines from the liver. The aim of this study is to evaluate the role of desferrioxamine in the prevention of pancreatic injury following major hepatectomy. Methods. Twelve Landrace pigs were subjected to a combination of major hepatectomy (70–75%), using the Pringle maneuver for 150 minutes, after constructing a porta-caval side-to-side anastomosis. The duration of reperfusion was 24 hours. Animals were randomly divided into a control group ( ) and a desferrioxamine group (DFX, ). DFX animals were treated with continuous IV infusion of desferrioxamine 100?mg/kg. Pancreatic tissue injury, c-peptide and amylase concentrations, and pancreatic tissue oxidative markers were evaluated. Results. Desferrioxamine-treated animals showed decreased c-peptide levels, decreased acinar cell necrosis, and decreased tissue malondialdehyde levels 24 hours after reperfusion compared with the control group. There was no difference in portal pressure or serum amylase levels between the groups. Conclusions. Desferrioxamine seems to attenuate pancreatic injury after major hepatectomy under vascular control possibly by preventing and reversing production and circulation of oxidative products. 1. Introduction Ischemia and reperfusion injury takes place during major hepatectomies due to the need for the use of vascular control techniques, as well as in liver transplantation and liver trauma. Although such maneuvers are invaluable in preventing excessive blood loss, they result in the production of cytokines and reactive oxygen species (ROS), which are responsible for induction of oxidative stress to the liver as well as to distant organs [1, 2]. Spillage of cytokines and inflammatory mediators has been shown to promote remote injury [3]. Hyperamylasemia and pancreatic injury has been well documented following major liver resections in patients with or without chronic liver disease [4, 5], as well as in experimental models [6]. Portal congestion, liver failure, and remote oxidative stress have been proposed as pathophysiologic mechanisms [3, 7]. Similar finding have been reported after liver transplantation [8, 9]. Although most often pancreatic injury can be subclinical, it can manifest as severe pancreatitis resulting in multiple organ failure, increasing morbidity and mortality following liver surgery [9, 10]. Desferrioxamine has been used in the past as an antioxidant in
References
[1]
V. Smyrniotis, C. Farantos, G. Kostopanagiotou, and N. Arkadopoulos, “Vascular control during hepatectomy: review of methods and results,” World Journal of Surgery, vol. 29, no. 11, pp. 1384–1396, 2005.
[2]
G. Garcea, A. Gescher, W. Steward, A. Dennison, and D. Berry, “Oxidative stress in humans following the Pringle manoeuvre,” Hepatobiliary and Pancreatic Diseases International, vol. 5, no. 2, pp. 210–214, 2006.
[3]
J. C. Yang, X. Q. Ji, C. L. Li, J. H. Lin, and X. G. Liu, “Impact of early-stage hepatic ischemia-reperfusion injury on other organs of rats,” Di Yi Jun Yi Da Xue Xue Bao, vol. 24, no. 9, pp. 1019–1022, 2004.
[4]
T. Hotta, Y. Kobayashi, K. Taniguchi et al., “Hyperamylasemia after hepatectomy in chronic liver disease patients,” Hepato-Gastroenterology, vol. 50, no. 52, pp. 1060–1065, 2003.
[5]
A. Tocchi, G. Mazzoni, G. Liotta, L. Lepre, G. Costa, and M. Miccini, “Increased blood amylase levels in the postoperative period after liver resection,” Il Giornale di Chirurgia, vol. 19, no. 6-7, pp. 262–264, 1998.
[6]
K. Kalimeris, C. Nastos, N. Papoutsidakis et al., “Iron chelation prevents lung injury after major hepatectomy,” Hepatology Research, vol. 40, no. 8, pp. 841–850, 2010.
[7]
S. Sjovall, T. Holmin, A. Evander, and U. Stenram, “Splenic and gastro-duodenal vein occlusion-influence on the pancreatic gland and on the outcome of experimental pancreatitis,” International Journal of Pancreatology, vol. 3, no. 2-3, pp. 143–149, 1988.
[8]
N. V. Krokos, D. Karavias, A. Tzakis et al., “Acute pancreatitis after liver transplantation: incidence and contributing factors,” Transplant International, vol. 8, no. 1, pp. 1–7, 1995.
[9]
P. Tissières, L. Simon, D. Debray et al., “Acute pancreatitis after orthotopic liver transplantation in children: incidence, contributing factor, and outcome,” Journal of Pediatric Gastroenterology and Nutrition, vol. 26, no. 3, pp. 315–320, 1998.
[10]
C. A. Camargo Jr., P. D. Greig, G. A. Levy, and P. A. Clavien, “Acute pancreatitis following liver transplantation,” Journal of the American College of Surgeons, vol. 181, no. 3, pp. 249–256, 1995.
[11]
K. Kalimeris, C. Nastos, N. Papoutsidakis et al., “Iron chelation prevents lung injury after major hepatectomy,” Hepatology Research, vol. 40, no. 8, pp. 841–850, 2010.
[12]
N. Arkadopoulos, C. Nastos, K. Kalimeris et al., “Iron chelation for amelioration of liver ischemia-reperfusion injury,” Hemoglobin, vol. 34, no. 3, pp. 265–277, 2010.
[13]
C. Nastos, K. Kalimeris, N. Papoutsidakis et al., “Antioxidant treatment attenuates intestinal mucosal damage and gut barrier dysfunction after major hepatectomy. Study in a porcine model,” Journal of Gastrointestinal Surgery, vol. 15, no. 5, pp. 809–817, 2011.
[14]
M. M. Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding,” Analytical Biochemistry, vol. 72, no. 1-2, pp. 248–254, 1976.
[15]
A. M. Jentzsch, H. Bachmann, P. Fürst, and H. K. Biesalski, “Improved analysis of malondialdehyde in human body fluids,” Free Radical Biology and Medicine, vol. 20, no. 2, pp. 251–256, 1996.
[16]
J. Schmidt, D. W. Rattner, K. Lewandrowski et al., “A better model of acute pancreatitis for evaluating therapy,” Annals of Surgery, vol. 215, no. 1, pp. 44–56, 1992.
[17]
N. Papoutsidakis, N. Arkadopoulos, V. Smyrniotis et al., “Early myocardial injury is an integral component of experimental acute liver failure—a study in two porcine models,” Archives of Medical Science, vol. 7, no. 2, pp. 217–223, 2011.
[18]
Y. Li, P. J. Zhang, C. Jin et al., “Protective effects of deferoxamine mesylate preconditioning on pancreatic tissue in orthotopic liver autotransplantation in rats,” Transplantation Proceedings, vol. 43, no. 5, pp. 1450–1455, 2011.
[19]
L. M. Colletti, D. G. Remick, and D. A. Campbell, “Desferal attenuates TNF release following hepatic ischemia/reperfusion,” Journal of Surgical Research, vol. 57, no. 4, pp. 447–453, 1994.
[20]
K. Meyer, M. F. Brown, G. Zibari et al., “ICAM-1 upregulation in distant tissues after hepatic ischemia/reperfusion: a clue to the mechanism of multiple organ failure,” Journal of Pediatric Surgery, vol. 33, no. 2, pp. 350–353, 1998.
[21]
H. Ochiai, S. Nakamura, S. Suzuki, S. Baba, and S. Baba, “Pancreatic damage resulting from temporary portal triad interruption during partial hepatectomy: protective effect of a prostaglandin I2 analogue,” Journal of Surgical Research, vol. 73, no. 2, pp. 129–136, 1997.
[22]
G. K. Glantzounis, H. J. Salacinski, W. Yang, B. R. Davidson, and A. M. Seifalian, “The contemporary role of antioxidant therapy in attenuating liver ischemia-reperfusion injury: a review,” Liver Transplantation, vol. 11, no. 9, pp. 1031–1047, 2005.
[23]
N. Arkadopoulos, D. Vlahakos, G. Kosotopanagiotou et al., “Iron chelation attenuates intracranial pressure and improves survival in a swine model of acute liver failure,” Liver Transplantation, vol. 14, no. 8, pp. 1116–1124, 2008.
[24]
J. L. Lelli Jr., S. Pradhan, and L. M. Cobb, “Prevention of postischemic injury in immature intestine by deferoxamine,” Journal of Surgical Research, vol. 54, no. 1, pp. 34–38, 1993.
[25]
L. A. Hernandez, M. B. Grisham, and D. N. Granger, “A role for iron in oxidant-mediated ischemic injury to intestinal microvasculature,” American Journal of Physiology, vol. 253, no. 1, part 1, pp. G49–G53, 1987.
[26]
C. Tokyol, S. Yilmaz, A. Kahraman, H. Cakar, and C. Polat, “The effects of desferrioxamine and quercetin on liver injury induced by hepatic ischaemia-reperfusion in rats,” Acta Chirurgica Belgica, vol. 106, no. 1, pp. 68–72, 2006.
[27]
G. T. Drugas, C. N. Paidas, A. M. Yahanda, D. Ferguson, and M. G. Clemens, “Conjugated desferoxamine attenuates hepatic microvascular injury following ischemia/reperfusion,” Circulatory Shock, vol. 34, no. 2, pp. 278–283, 1991.
[28]
R. Omar, I. Nomikos, G. Piccorelli, J. Savino, and N. Agarwal, “Prevention of postischaemic lipid peroxidation and liver cell injury by iron chelation,” Gut, vol. 30, no. 4, pp. 510–514, 1989.
[29]
J. M. Colet, E. Cetiner, B. E. Hedlund, and R. N. Muller, “Assessment of microvascular integrity in the isolated perfused rat liver by contrast-enhanced MRI. Attenuation of reperfusion injury by conjugated deferoxamine,” Magnetic Resonance in Medicine, vol. 36, no. 5, pp. 753–757, 1996.
[30]
S. Sanan, G. Sharma, R. Malhotra, D. P. Sanan, P. Jain, and P. Vadhera, “Protection by desferrioxamine against histopathological changes of the liver in the host-oligaemic phase of clinical haemorrhagic shock in dogs: correlation with improved survival rate and recovery,” Free Radical Research Communications, vol. 6, no. 1, pp. 29–38, 1989.
[31]
G. G. Kostopanagiotou, K. A. Kalimeris, N. P. Arkadopoulos et al., “Desferrioxamine attenuates minor lung injury following surgical acute liver failure,” European Respiratory Journal, vol. 33, no. 6, pp. 1429–1436, 2009.
[32]
S. C. Nicholson, M. Squier, D. J. P. Ferguson, Z. Nagy, S. Westaby, and R. D. Evans, “Effect of desferrioxamine cardioplegia on ischemia-reperfusion injury in isolated rat heart,” Annals of Thoracic Surgery, vol. 63, no. 4, pp. 1003–1011, 1997.
[33]
J. Pincemail, J. O. Defraigne, O. Detry, C. Franssen, M. Meurisse, and R. Limet, “Ischemia-reperfusion injury of rabbit kidney: comparative effects of desferrioxamine and N-Acetylcysteine as antioxidants,” Transplantation Proceedings, vol. 32, no. 2, pp. 475–476, 2000.
[34]
Y. X. Li, S. J. Ding, L. Xiao, W. Guo, and Q. Zhan, “Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1α and erythropoietin,” Neuroscience Bulletin, vol. 24, no. 2, pp. 89–95, 2008.
[35]
D. Galaris, A. Barbouti, and P. Korantzopoulos, “Oxidative stress in hepatic Ischemia-reperfusion injury: the role of antioxidants and iron chelating compounds,” Current Pharmaceutical Design, vol. 12, no. 23, pp. 2875–2890, 2006.
[36]
P. Caraceni, D. H. Van Thiel, and A. B. Borle, “Dual effect of deferoxamine on free radical formation and reoxygenation injury in isolated hepatocytes,” American Journal of Physiology, vol. 269, no. 1, part 1, pp. G132–G137, 1995.
[37]
Y. Kawano, K. Akimaru, K. Takubo et al., “Jejunectomy can reduce excessively elevated portal pressure after major hepatectomy in beagle dogs,” Journal of Surgical Research, vol. 130, no. 1, pp. 24–33, 2006.
[38]
H. Wang, N. Ohkohchi, Y. Enomoto et al., “Effect of portocaval shunt on residual extreme small liver after extended hepatectomy in porcine,” World Journal of Surgery, vol. 30, no. 11, pp. 2014–2022, 2006.
[39]
E. Morsiani, A. Aleotti, and D. Ricci, “Haemodynamic and ultrastructural observations on the rat liver after two-thirds partial hepatectomy,” Journal of Anatomy, vol. 192, no. 4, pp. 507–515, 1998.
[40]
Y. Suminaga and Y. Yasuda, “Hepatic hemodynamics after hepatectomy and the effect of administration of glucagon,” Nippon Geka Gakkai Zasshi, vol. 91, no. 5, pp. 594–604, 1990.
[41]
N. Arkadopoulos, G. Defterevos, C. Nastos et al., “Development of a porcine model of post-hepatectomy liver failure,” Journal of Surgical Research, vol. 170, no. 2, pp. e233–e242, 2011.
[42]
J. T. Tamsma, A. F. M. Schaapherder, H. Van Bronswijk et al., “Islet cell hormone release immediately after human pancreatic transplantation: a marker of tissue damage associated with cold ischemia,” Transplantation, vol. 56, no. 5, pp. 1119–1123, 1993.
[43]
N. Arkadopoulos, C. Nastos, G. Defterevos, K. Kalimeris, N. Papoutsidakis, and I. Andreadou, “Pancreatic injury after major hepatectomy: a study in a porcine model,” Surgery Today, vol. 42, no. 4, pp. 368–375, 2012.
[44]
H. Jaeschke, “Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning,” American Journal of Physiology, vol. 284, no. 1, pp. G15–G26, 2003.
[45]
D. L. Carden and D. N. Granger, “Pathophysiology of ischaemia-reperfusion injury,” The Journal of Pathology, vol. 190, no. 3, pp. 255–266, 2000.
[46]
I. H. Alexandris, S. F. Assimakopoulos, C. E. Vagianos et al., “Oxidative state in intestine and liver after partial hepatectomy in rats. Effect of bombesin and neurotensin,” Clinical Biochemistry, vol. 37, no. 5, pp. 350–356, 2004.